Trial Profile
Multicenter, Open Label, Prospective, Phase IV Interventional Study in Adult Indian Patients to Evaluate the Safety and Efficacy of MyHep LVIRTM (ledipasvir/sofosbuvir, Fixed Dose Combination) in HCV genotype 1 infection and the combination of MyHepTM (sofosbuvir) and MyDeklaTM (daclatasvir) in HCV genotype 3 infection
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Mylan Laboratories Limited
- 11 Sep 2018 Status changed from not yet recruiting to recruiting.
- 22 Jun 2018 New trial record